Targeting the epigenome in ovarian cancer

Future Oncology

Volumn 8, Issue 2, 2012, Pages 151-164

  Murphy, Susan K ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

5 azacytidine; 5 hydroxymethylcytosine; bellinostat; cancer stem cells; decitabine; DNA methylation; DNA methyltransferase inhibitors; histone deacetylase inhibitors; ovarian cancer; vorinostat

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 HYDROXYMETHYLCYTOSINE; ALPHA TUBULIN; AZACITIDINE; B RAF KINASE; BELINOSTAT; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GEMCITABINE; GENOMIC DNA; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; K RAS PROTEIN; PACLITAXEL; POLO LIKE KINASE 2; PROTEIN P53; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; THYMINE DNA GLYCOSYLASE; TOPOTECAN; TRANSCRIPTION FACTOR SOX1; TRANSCRIPTION FACTOR YY1; UNINDEXED DRUG; VORINOSTAT;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL CULTURE; CELL CYCLE ARREST; CELL DIVISION; CELL SURVIVAL; CENTROMERE; COLON; COLON CANCER; CPG ISLAND; CYTOREDUCTIVE SURGERY; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; ENDOMETRIOSIS; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HISTONE MODIFICATION; HUMAN; ILLUMINATION; LIVER METASTASIS; LOW DRUG DOSE; MYELOPOIESIS; NONHUMAN; OVARY CANCER; PERITONEAL FLUID; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTO ONCOGENE; RECEPTOR DOWN REGULATION; REVIEW; SOLID TUMOR; SOMATIC CELL; STEM CELL; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; X CHROMOSOME;

ANIMALS; ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS;

EID: 84857348466     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.152     Document Type: Review

References (79)

1. Sfakianos GP, Havrilesky LJ. A review of cost-effectiveness studies in ovarian cancer. Cancer Control 18(1), 59-64 (2011).
2. Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 95(Suppl. 1), S161-S192 (2006).
3. Kosary CL. Cancer of the ovary. In: SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. Ries LAG, Young JL, Keel GE et al (Eds). National Cancer Institute, SEER Program, Bethesda, MD, USA, 113-144 (2007).
4. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 34(3), 433-443 (2010).
5. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat. Rev. Cancer 10(11), 803-808 (2010).
6. Kindelberger DW, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 31(2), 161-169 (2007). (Pubitemid 46175016)
7. Lee Y, Miron A, Drapkin R et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211(1), 26-35 (2007). (Pubitemid 46092026)
8. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363(16), 1532-1543 (2010).
9. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 14(5), 1291-1295 (2008). (Pubitemid 351413906)
10. Ahmed AA, Etemadmoghadam D, Temple J et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221(1), 49-56 (2010).
11. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609-615 (2011).
12. Swanton C, Nicke B, Schuett M et al. Chromosomal instability determines taxane response. Proc. Natl Acad. Sci. USA 106(21), 8671-8676 (2009).
13. Matsumura N, Huang Z, Baba T et al. Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol. Cancer Res. 7(2), 210-220 (2009).
14. Syed N, Coley HM, Sehouli J et al. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res. 71(9), 3317-3327 (2011).
15. Ahmed AA, Lu Z, Jennings NB et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18(2), 109-121 (2010).
16. Zhu Q, Pao GM, Huynh AM et al. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 477(7363), 179-184 (2011).
17. Norquist B, Wurz KA, Pennil CC et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29(22), 3008-3015 (2011).
18. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 447(7143), 433-440 (2007). (Pubitemid 46816750)
19. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J. Clin. Oncol. 29(5), 516-523 (2011).
20. Blackledge NP, Zhou JC, Tolstorukov MY et al. CpG islands recruit a histone H3 lysine 36 demethylase. Mol. Cell 38(2), 179-190 (2010).
21. Thomson JP, Skene PJ, Selfridge J et al. CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature 464(7291), 1082-1086 (2010).
22. Medvedeva YA, Fridman MV, Oparina NJ et al. Intergenic, gene terminal, and intragenic CpG islands in the human genome. BMC Genomics 11, 48 (2010).
23. Ito S, Shen L, Dai Q et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333(6047), 1300-1303 (2011).
24. He YF, Li BZ, Li Z et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333(6047), 1303-1307 (2011).
25. Cortellino S, Xu J, Sannai M et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146(1), 67-79 (2011).
26. Li W, Liu M. Distribution of 5-hydroxymethylcytosine in different human tissues. J. Nucleic Acids 2011, 870726 (2011).
27. Ko M, Huang Y, Jankowska AM et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468(7325), 839-843 (2010).
28. Ito S, D'Alessio AC, Taranova OV et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466(7310), 1129-1133 (2010).
29. Kim H, Park J, Jung Y et al. DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells. Int. J. Oncol. 36(6), 1563-1572 (2010).
30. Fisher CL, Fisher AG. Chromatin states in pluripotent, differentiated, and reprogrammed cells. Curr. Opin Genet. Dev. 21(2), 140-146 (2011).
31. Wei Y, Xia W, Zhang Z et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 47(9), 701-706 (2008).
32. Visvader JE. Cells of origin in cancer. Nature 469(7330), 314-322 (2011).
33. Kondoh E, Mori S, Yamaguchi K et al. Targeting slow-proliferating ovarian cancer cells. Int. J. Cancer 126(10), 2448-2456 (2010).
34. Bapat SA, Jin V, Berry N et al. Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. Epigenetics 5(8), 716-729 (2010).
35. Kryczek I, Liu S, Roh M et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int. J. Cancer 130(1), 29-39 (2012).
36. Zhang S, Balch C, Chan MW et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68(11), 4311-4320 (2008).
37. Claes B, Buysschaert I, Lambrechts D. Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy. Heredity 105(1), 152-160 (2010).
38. Mortusewicz O, Schermelleh L, Walter J, Cardoso MC, Leonhardt H. Recruitment of DNA methyltransferase I to DNA repair sites. Proc. Natl Acad. Sci. USA 102(25), 8905-8909 (2005). (Pubitemid 40881051)
39. Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 67(3), 946-950 (2007).
40. Barton CA, Hacker NF, Clark SJ, O'Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol. Oncol. 109(1), 129-139 (2008).
41. Shivapurkar N, Gazdar AF. DNA methylation based biomarkers in non-invasive cancer screening. Curr. Mol. Med. 10(2), 123-132 (2010).
42. Su HY, Lai HC, Lin YW et al. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int. J. Cancer 124(2), 387-393 (2009).
43. Wei SH, Balch C, Paik HH et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin. Cancer Res. 12(9), 2788-2794 (2006).
44. Watts GS, Futscher BW, Holtan N et al. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med. Genomics 1, 47 (2008).
45. Houshdaran S, Hawley S, Palmer C et al. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS ONE. 5(2), E9359 (2010).
46. Shih IeM, Chen L, Wang CC et al. Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am. J. Obstet. Gynecol. 203(6), 584.e1-284.e22 (2010).
47. Matsumura N, Huang Z, Mori S et al. Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res. 21(1), 74-82 (2011).
48. Teschendorff AE, Menon U, Gentry-Maharaj A et al. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS ONE. 4(12), E8274 (2009).
49. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin. Cancer Res. 15(12), 3938-3946 (2009).
50. Matei D, Sill MW, Lankes HA et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J. Clin. Oncol. 29(1), 69-75 (2011).
51. Takai N, Narahara H. Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J. Oncol. 2010, 458431 (2010).
52. Meng CF, Su B, Li W. DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells. Mol. Med. Report 4(6), 1273-1278 (2011).
53. Li M, Balch C, Montgomery JS et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med. Genomics 2(1), 34 (2009).
54. Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br. J. Cancer 100(5), 758-763 (2009).
55. Chen MY, Liao WS, Lu Z et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer 117(19), 4424-4438 (2011).
56. Yap OW, Bhat G, Liu L, Tollefsbol TO. Epigenetic modifications of the estrogen receptor beta gene in epithelial ovarian cancer cells. Anticancer Res. 29(1), 139-144 (2009).
57. Matei DE, Nephew KP. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol. Oncol. 116(2), 195-201 (2010).
58. Modesitt SC, Sill M, Hoffman JS, Bender DP. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 109(2), 182-186 (2008).
59. Fu S, Hu W, Iyer R et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117(8), 1661-1669 (2011).
60. Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am. J. Obstet. Gynecol. 200(2), 177 (2009).
61. Fang F, Balch C, Schilder J et al. A Phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 116(17), 4043-4053 (2010).
62. Cooper AL, Greenberg VL, Lancaster PS et al. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol. Oncol. 104(3), 596-601 (2007). (Pubitemid 46240243)
63. Qian X, LaRochelle WJ, Ara G et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol. Cancer Ther. 5(8), 2086-2095 (2006). (Pubitemid 44336581)
64. Mackay HJ, Hirte H, Colgan T et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur. J. Cancer 46(9), 1573-1579 (2010).
65. Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl Res. 3(2), 166-179 (2011).
66. Baba T, Convery PA, Matsumura N et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28(2), 209-218 (2009).
67. Curley MD, Therrien VA, Cummings CL et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27(12), 2875-2883 (2009).
68. Rizzo S, Hersey JM, Mellor P et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther. 10(2), 325-335 (2011).
69. Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br. J. Cancer 102(8), 1276-1283 (2010).
70. Landen CN Jr, Goodman B, Katre AA et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol. Cancer Ther. 9(12), 3186-3199 (2010).
71. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum. Pathol. 42(7), 918-931 (2011).
72. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT et al. Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc. Natl Acad. Sci. USA 103(30), 11154-11159 (2006). (Pubitemid 44156488)
73. Murphy SK. Targeting ovarian cancer-initiating cells. Anticancer Agents Med. Chem. 10(2), 157-163 (2010).
74. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26(37), 5541-5552 (2007). (Pubitemid 47255934)
75. Wei X, Dombkowski D, Meirelles K et al. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc. Natl Acad. Sci. USA 107(44), 18874-18879 (2010).
76. Beltran A, Parikh S, Liu Y et al. Re-activation of a dormant tumor suppressor gene MASPIN by designed transcription factors. Oncogene 26(19), 2791-2798 (2007). (Pubitemid 46663828)
77. Alvarez Secord A, Darcy KM, Hutson A et al. The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a Gynecologic Oncology Group study. Gynecol. Oncol. 123(2), 314-319 (2011).
78. Meister GE, Chandrasegaran S, Ostermeier M. Heterodimeric DNA methyltransferases as a platform for creating designer zinc finger methyltransferases for targeted DNA methylation in cells. Nucleic Acids Res. 38(5), 1749-1759 (2010).
79. Jeltsch A, Jurkowska RZ, Jurkowski TP et al. Application of DNA methyltransferases in targeted DNA methylation. Appl. Microbiol. Biotechnol. 75(6), 1233-1240 (2007). (Pubitemid 46976679)